Kenneth Patrick Mulvany
Direktor/Vorstandsmitglied bei BENEVOLENTAI
Vermögen: 23 Mio $ am 30.04.2024
Profil
Kenneth Patrick Mulvany is the founder of Proximagen Group Plc, which was founded in 2005.
He served as the Chief Executive Officer from 2005 to 2012.
He was also the founder of BenevolentAI Ltd., founded in 2015, where he held the title of Executive Chairman from 2015 to 2021.
Additionally, he was the founder of BenevolentAI SA, founded in 2013, where he served as a Non-Executive Director from 2013 to 2022.
Dr. Mulvany is also the founder of BenevolentAI.
Currently, he holds the position of Deputy Chairman at BenevolentAI SA since 2024 and has been a Director at BenevolentAI Bio Ltd.
since 2013.
He is also a Trustee at The Cure Parkinson's Trust.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
BENEVOLENTAI S.A.
23,78% | 31.12.2022 | 33 912 333 ( 23,78% ) | 23 Mio $ | 30.04.2024 |
Aktive Positionen von Kenneth Patrick Mulvany
Unternehmen | Position | Beginn |
---|---|---|
BENEVOLENTAI | Direktor/Vorstandsmitglied | 02.05.2024 |
BenevolentAI Bio Ltd.
BenevolentAI Bio Ltd. Packaged SoftwareTechnology Services Part of BenevolentAI SA, BenevolentAI Bio Ltd. is a clinical-stage AI-enabled drug discovery and British development company founded in 2013. The company is based in London, UK. BenevolentAI Bio uses AI to augment scientific ingenuity in the drug discovery process, from target identification to clinical development, with the goal of improving the probability of clinical success. The company has refined and formalized its approach to sustainability under the direction of the newly established environmental, social, and governance (ESG) governance structure and teams. BenevolentAI Bio's AI-enabled Benevolent Platform™ empowers scientists to uncover new insights from data, helping to accelerate innovation and increase the probability of discovering a successful drug. | Direktor/Vorstandsmitglied | 13.11.2013 |
The Cure Parkinson's Trust | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Kenneth Patrick Mulvany
Unternehmen | Position | Ende |
---|---|---|
BENEVOLENTAI | Gründer | 30.06.2022 |
Minster Pharmaceuticals Plc
Minster Pharmaceuticals Plc Pharmaceuticals: MajorHealth Technology Minster Pharmaceuticals Plc develops pharmaceutical compounds for the treatment of neurological and psychiatric conditions. The company operates in Tonabersat and Sabcomeline segments. The Tonabersat segment is for the prevention and treatment of migraine. The Sabcomeline segment is for the management of cognitive decline and negative symptoms in schizophrenia. Minster Pharmaceuticals was founded by Robert Stubbs and Paul Sharpe in 2001 and is headquartered in London, the United Kingdom. | Direktor/Vorstandsmitglied | - |
BenevolentAI Ltd.
BenevolentAI Ltd. Packaged SoftwareTechnology Services Part of BenevolentAI SA, BenevolentAI Ltd. develops artificial intelligence applications. The company is based in London, UK. The British company was founded in 2015 by Kenneth Patrick Mulvany, Ivan Griffin, Michael Brennan. BenevolentAI was acquired by Odyssey Acquisition SA on April 22, 2022 for $1,087.33 million. | Gründer | - |
Proximagen Group Plc
Proximagen Group Plc Miscellaneous Commercial ServicesCommercial Services Proximagen Group Plc engages in the business of discovery and development of therapeutic treatments. The company was founded by Jenner Peter on November 2003 and is headquartered in Cambridge, the United Kingdom. | Gründer | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
BENEVOLENTAI | Health Technology |
Private Unternehmen | 5 |
---|---|
Proximagen Group Plc
Proximagen Group Plc Miscellaneous Commercial ServicesCommercial Services Proximagen Group Plc engages in the business of discovery and development of therapeutic treatments. The company was founded by Jenner Peter on November 2003 and is headquartered in Cambridge, the United Kingdom. | Commercial Services |
Minster Pharmaceuticals Plc
Minster Pharmaceuticals Plc Pharmaceuticals: MajorHealth Technology Minster Pharmaceuticals Plc develops pharmaceutical compounds for the treatment of neurological and psychiatric conditions. The company operates in Tonabersat and Sabcomeline segments. The Tonabersat segment is for the prevention and treatment of migraine. The Sabcomeline segment is for the management of cognitive decline and negative symptoms in schizophrenia. Minster Pharmaceuticals was founded by Robert Stubbs and Paul Sharpe in 2001 and is headquartered in London, the United Kingdom. | Health Technology |
BenevolentAI Bio Ltd.
BenevolentAI Bio Ltd. Packaged SoftwareTechnology Services Part of BenevolentAI SA, BenevolentAI Bio Ltd. is a clinical-stage AI-enabled drug discovery and British development company founded in 2013. The company is based in London, UK. BenevolentAI Bio uses AI to augment scientific ingenuity in the drug discovery process, from target identification to clinical development, with the goal of improving the probability of clinical success. The company has refined and formalized its approach to sustainability under the direction of the newly established environmental, social, and governance (ESG) governance structure and teams. BenevolentAI Bio's AI-enabled Benevolent Platform™ empowers scientists to uncover new insights from data, helping to accelerate innovation and increase the probability of discovering a successful drug. | Technology Services |
BenevolentAI Ltd.
BenevolentAI Ltd. Packaged SoftwareTechnology Services Part of BenevolentAI SA, BenevolentAI Ltd. develops artificial intelligence applications. The company is based in London, UK. The British company was founded in 2015 by Kenneth Patrick Mulvany, Ivan Griffin, Michael Brennan. BenevolentAI was acquired by Odyssey Acquisition SA on April 22, 2022 for $1,087.33 million. | Technology Services |
The Cure Parkinson's Trust |